SCHEMBL4683247

SCHEMBL4683247

CC[C@H](N)C(=O)NNC(=O)N[C@@H](Cc1ccc2ccccc2c1)C(=O)N[C@@H](Cc1cccc(F)c1)C(N)=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FCER2 P06734 5/20 0.49
MMP9 P14780 2/20 0.49
MMP3 P08254 1/20 0.49
KISS1R Q969F8 4/20 0.46
MME P08473 1/20 0.44
ACE P12821 1/20 0.44
CPA1 P15085 1/20 0.44
ACE2 Q9BYF1 1/20 0.44
OPRD1 P41143 1/20 0.44
PIN1 Q13526 1/20 0.42
CTSL P07711 1/20 0.41
CTSB P07858 1/20 0.41
CTSS P25774 1/20 0.41
PTPN1 P18031 1/20 0.41
MMP8 P22894 1/20 0.41
PSMB1 P20618 1/20 0.41
PSMB5 P28074 1/20 0.41
PSMB2 P49721 1/20 0.41
MC5R P33032 2/20 0.40
MC1R Q01726 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4678251 1.00 FCER2 (0.49) FCER2MMP9MMP3KISS1RMME
SCHEMBL4680362 0.90 KISS1R (0.47) FCER2MMP9MMP3KISS1RMME
SCHEMBL4680502 0.90 KISS1R (0.47) FCER2MMP9MMP3KISS1RMME
SCHEMBL4675732 0.86 KISS1R (0.49) FCER2MMP9MMP3KISS1RCTSL
SCHEMBL4676548 0.86 KISS1R (0.49) FCER2MMP9MMP3KISS1RCTSL
SCHEMBL4682112 0.86 FCER2 (0.51) FCER2MMP9MMP3KISS1RMME
SCHEMBL4680626 0.86 FCER2 (0.51) FCER2MMP9MMP3KISS1RMME
SCHEMBL8301555 0.86 FCER2 (0.48) FCER2MMP9MMP3KISS1RMME
SCHEMBL4678748 0.83 GHSR (0.59) KISS1R
SCHEMBL4676288 0.83 GHSR (0.59) KISS1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1633702-B1 PROTEASE INHIBITORS PROZYMEX AS (DK) 2008-07-02 EP claimed
US-20070155803-A1 Protease inhibitors PROZYMEX A/S (DK) 2007-07-05 US claimed
EP-1975153-A2 Protease inhibitors Prozymex A/S (DK) 2008-10-01 EP disclosed
EP-1975153-A2 Protease inhibitors Prozymex A/S (DK) 2008-10-01 EP disclosed
EP-1633702-B1 PROTEASE INHIBITORS PROZYMEX AS (DK) 2008-07-02 EP disclosed
EP-1633702-B1 PROTEASE INHIBITORS PROZYMEX AS (DK) 2008-07-02 EP disclosed
US-20070155803-A1 Protease inhibitors PROZYMEX A/S (DK) 2007-07-05 US disclosed
US-20070155803-A1 Protease inhibitors PROZYMEX A/S (DK) 2007-07-05 US disclosed
US-20070155803-A1 Protease inhibitors PROZYMEX A/S (DK) 2007-07-05 US disclosed
WO-2004106289-A1 PROTEASE INHIBITORS PROZYMEX A/S (DK) 2004-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155803-A1 Protease inhibitors DPP7, DPP9, DPP3 FCER2 588/4885MMP9 78/4885MMP3 33/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.